drugset / Trial / NCT06126497
Study Evaluating Safety and Efficacy of Ropanicant in MDD Patients
RandomizedParallel-groupOpen-labelTreatment
Summary
This is an open-label, parallel-group study to evaluate the safety and efficacy of ropanicant in participants with moderate to severe Major Depressive Disorder (MDD).
Timeline
- Start
- 2024-02-05
- Primary completion
- 2024-07-19
- Completion
- 2024-07-19
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ropanicant | Small molecule | 1 unknown | — |
| Subject | Ropanicant | Small molecule | 2 unknown | — |
| Subject | Ropanicant | Small molecule | 3 mg | — |